No Data
No Data
Press Release: Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $48
Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session
We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m